Roivant Sciences Ltd. reported its financial results for the nine months ended December 31, 2025. Total revenue for the period was USD 5.74 million. The company recorded a net loss attributable to shareholders of USD 602.77 million for the nine-month period. Research and development expenses totaled USD 482.87 million, while cost of revenues amounted to USD 0.97 million. Income tax expense was USD 34.98 million for the same period. For the third quarter, Roivant Sciences reported revenue of USD 5.74 million and a net loss attributable to shareholders of USD 265.89 million. During the period, Roivant Sciences continued to advance its pipeline, which includes brepocitinib, a small molecule inhibitor of TYK2 and JAK1 being developed for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The pipeline also features IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn and being developed for several IgG-mediated autoimmune indications. The company reaffirmed its commitment to accelerating the development and commercialization of medicines that address significant unmet medical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001635088-26-000011), on February 06, 2026, and is solely responsible for the information contained therein.